With regard to Revascor (MSB/ Teva) I found it concerning that there are a number of competitors for the same indication and expecting results well before that of Revascor!
MPC-100-IM in CHF
Exhibit 5: Selected stem cell and gene therapies in Phase II or III trials for CHF Company Product Therapy class Status Target CHF patients Notes:
Mesoblast Teva Revascor Stem cell (allogeneic) Phase III-ready Ischaemic and non-ischaemic, NYHA II or III, LVEF<40 Allogeneic (bone marrow-derived) mesenchymal precursor cells (MPC). Phase III readout August 2018.
Cardio3 C-Cure Stem cell (autologous) 240-pt Phase III Ischaemic, NYHA II to IV, LVEF<30% Autologous (bone marrow-derived) cardiopoietic mesenchymal stem cells. Expected Phase III readout 2015.
Bioheart MyoCell Stem cell (autologous) 170-pt Phase II/III Ischaemic (post-AMI), NYHA II to IV, LVEF<35% Autologous (skeletal muscle-derived) myoblasts. Expected Phase II/III estimated completion February 2017.
Celladon Mydicar Gene therapy 200-pt Phase IIb Ischaemic or non-ischaemic, NHYA II to IV, LVEF<35% Gene transfer using a viral vector (AAV1) to deliver the SERCA2a gene. Expected Phase IIb readout in Q116.
Aastrom Ixmyelocel Stem cell (autologous) 108-pt Phase II Ischaemic, NYHA III or IV, LVEF<35% Autologous (bone marrow-derived) CD90+ mesenchymal cells and CD14+ monocytes. Expected Phase II readout Q315.
Edison Research, page-6
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.33 |
Change
0.045(3.50%) |
Mkt cap ! $1.518B | |||
| Open | High | Low | Value | Volume |
| $1.30 | $1.35 | $1.30 | $2.885M | 2.183M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.33 | 7070 | 1 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |